On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.

Cassava Sciences SAVA, a clinical-stage biotech ... setback after it reported that its lead and only pipeline drug, simufilam, failed to meet the primary endpoints in a late study for AD.

Take two at bedtime. That’s what the label on the side of the bottle says, and that’s what you’ll do. You want to feel better soon — your health and well-being are important — so you’ll do as you’re ...

Cassava Sciences is working on bringing its own Alzheimer ... The company’s CEO, Rick Barry, recently announced in an open letter that simufilam, its potential Alzheimer’s therapy, had ...

That’s what the label on the side of the bottle says, and that’s what you’ll do. You want to feel better soon — your health and well-being are important — so you’ll do as you’re told ...